Search

Displaying results 4311 - 4320 of 8575 in total
  1. Drug

    Ferric oxide

    go.drugbank.com/drugs/DB11576
    ApprovedInvestigational

    It is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite.

  2. Drug

    Meningococcal polysaccharide vaccine group Y

    go.drugbank.com/drugs/DB13888
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.

  3. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    [L64061] The virus is engineered to express a fusogenic glycoprotein derived from gibbon ape leukemia virus (GALV-GP-R–) and human granulocyte-macrophage colony-stimulating factor (GM-CSF), and has its … [L64061,L64062] It is the second oncolytic viral therapy approved in the United States, following talimogene laherparepvec (T-VEC, Imlygic) in 2015, and the first approved for melanoma that has progressed

  4. Drug

    BMS-813160

    go.drugbank.com/drugs/DB16240
    Investigational

    BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

  5. Drug

    Ciltacabtagene autoleucel

    go.drugbank.com/drugs/DB16738
    ApprovedInvestigational

    [A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744] … [A245854] B-cell maturation antigen (BCMA) is a transmembrane glycoprotein member of the tumor necrosis factor receptor superfamily 17 (TNFRSF17) which is used as a biomarker for multiple myeloma.

  6. Drug

    Galsulfase

    go.drugbank.com/drugs/DB01279
    ApprovedInvestigational

    The recombinant protein is comprised of 495 amino acids and contains six asparagine-linked glycosylation sites, four of which carry a bis mannose-6-phosphate manose7 oligosaccharide for specific cellular

  7. Drug

    BacTRL-spike

    go.drugbank.com/drugs/DB15811
    Investigational

    The vaccine was developed by Symvivo Corporation. … As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine.

  8. Drug

    5-fluorouridine

    go.drugbank.com/drugs/DB01629
    Investigational

    These are compounds comprising a pyrimidine base attached to a sugar. 5-fluorouridine is known to target uridine phosphorylase. … 5-fluorouridine is also known as FUrd, 5-Fluorouracil 1-beta-D-ribofuranoside, 5-Fur, or 5-Fluoro-uridine. 5-fluorouridine is a solid.

  9. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual

  10. Drug

    Casdatifan

    go.drugbank.com/drugs/DB21701
    Investigational

    Casdatifan has a monoisotopic molecular weight of 439.09 Da. … Casdatifan is under investigation in clinical trial NCT07000149 (A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC)